Bloomberg Reported Sunday Guardant Health Decided Against Buying NeoGenomics
https://www.bloomberg.com/news/articles/2021-10-04/guardant-health-is-said-to-decide-against-neogenomics-takeover
35 Stocks Moving In Friday’s Mid-Day Session
Gainers
Biomerica, Inc. (NASDAQ: BMRA) shares climbed 38.3% to $6.23. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system.
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
Bloomberg reported that Guardant Health Inc (NASDAQ:GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ:NEO), citing people familiar with the matter. Related: Precision…
New Data at IASLC 2021 World Conference On Lung Cancer Demonstrates Advantages Of Using the Guardant360 Liquid Biopsy Blood Test For Comprehensive Genomic Profiling In Advanced Lung Cancer
Guardant Health, Inc. (NASDAQ:GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360® liquid biopsy test for clinical
Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates
After the market close on Thursday, Guardant Health Inc (NASDAQ:GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the…
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Guardant Health Q2 EPS $(0.96) Misses $(0.87) Estimate, Sales $92.10M Beat $84.61M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.87) by 10.34 percent. This is a 68.42 percent decrease over losses of $(0.57) per share from